Tetraphase Pharmaceuticals Revenue, Profits - TTPH Quarterly Income Statement

Add to My Stocks
$3.01 $0.11 (3.79%) TTPH stock closing price Sep 19, 2018 (Closing)

Financial analysis of Tetraphase Pharmaceuticals involves more than just checking the Tetraphase Pharmaceuticals stock price, by looking at the financial statements of the company in detail. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $11.58M for 2018 Q2 impacts the TTPH stock. Investors typically check year over year or quarter over quarter revenue growth. The Tetraphase Pharmaceuticals profit and loss statement for 2018 Q2 shows a net profit of $-9.54M. Profits for last year was $-21.58M. Apart from this an investor should also check Tetraphase Pharmaceuticals assets and Tetraphase Pharmaceuticals free cash flow.

View and download details of revenue and profits for Tetraphase Pharmaceuticals for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Tetraphase Pharmaceuticals Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
Tetraphase Pharmaceuticals Gross Profit
Research & Development Expense14.37M18.12M18.48M28.77M28.51M25.94M19.31M17.19M13.74M13.52M
Selling General & Admin Expense7.17M5.7M7.88M5.6M5.06M5.13M4.36M4.85M4.75M5.25M
Income Before Depreciation Depletion Amortization-9.96M-21.94M-23.82M-30.31M-31.99M-29.59M-22.57M-21.19M-17.26M-16.81M
Depreciation Depletion Amortization----------
Non Operating Income----------
Interest Expense----------
Tetraphase Pharmaceuticals Pretax Income
Provision for Income Taxes----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-9.54M-21.58M-23.48M-30.01M-31.81M-29.46M-22.46M-21.11M-17.17M-16.74M
Extraordinary Items & Discontinued Operations----------
Tetraphase Pharmaceuticals Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS51.84M51.6M51.42M47.35M38.27M37.09M36.89M36.69M36.63M36.6M
Average Shares used to compute Basic EPS51.84M51.6M51.42M47.35M38.27M37.09M36.89M36.69M36.63M36.6M
Income Before Nonrecurring Items-9.54M-21.58M-23.48M-30.01M-31.81M-29.46M-22.46M-21.11M-17.17M-16.74M
Income from Nonrecurring Items----------
Tetraphase Pharmaceuticals Earnings Per Share Basic Net
Tetraphase Pharmaceuticals Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.18-0.42-0.46-0.63-0.83-0.79-0.61-0.58-0.47-0.46
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on Tetraphase Pharmaceuticals stock analysis. It helps to look at the following income statement items:

  • Topline: A growing topline, as seen from the Tetraphase Pharmaceuticals revenue chart, as is the case with Tetraphase Pharmaceuticals indicates a growing business. One needs to compare the QoQ topline or sales growth of TTPH stock with its peers like RDHL stock and AVDL stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-9.54M for Tetraphase Pharmaceuticals for 2018 Q2. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the TTPH income statement, one can check the Tetraphase Pharmaceuticals historical stock prices to check how the price has moved with time.

Tetraphase Pharmaceuticals Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield